Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
CC transcript
Quarterly results
Appointed director
Viracta Therapeutics, Inc. (VIRX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/04/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "FORM 8-K",
"Viracta Therapeutics to Host R&D Day Highlighting Nana-val in Epstein-Barr Virus -Associated Cancers",
"Corporate Presentation"
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/14/2023 8-K Quarterly results
Docs: "Viracta Therapeutics, Inc. Selected Balance Sheet Highlights June 30, December 31, 2023 2022 Cash, cash equivalents and short-term investments $ 72,867 $ 91,043 Total assets $ 76,859 $ 95,991 Total liabilities $ 36,077 $ 34,888 Stockholders' equity $ 40,782 $ 61,103 Viracta Therapeutics, Inc. Condensed Consolidated Statement of Operations and Comprehensive Loss Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Operating expenses: Research and development $ 8,197 $ 6,324 $ 15,804 $ 12,420 General and administrative 4,253 4,181 8,853 8,517 Total operating expenses 12,450 10,505 24,657 20,937 Loss from operations Total other expense Net loss Unrealized gain on short-term investments — 63 — Comprehensive loss Net loss per share, basic and diluted $ $ $ $ Weight..."
08/07/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Head of Investor Relations"
06/09/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/26/2023 144 Form 144 - Report of proposed sale of securities:
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/08/2023 8-K Quarterly results
Docs: "-- Financial tables attached – Viracta Therapeutics, Inc. Selected Balance Sheet Highlights March 31, December 31, 2023 2022 Cash, cash equivalents and short-term investments $ 80,332 $ 91,043 Total assets $ 85,781 $ 95,991 Total liabilities $ 34,668 $ 34,888 Stockholders' equity $ 51,113 $ 61,103 Viracta Therapeutics, Inc. Condensed Consolidated Statement of Operations and Comprehensive Loss Three Months Ended March 31, 2023 2022 Operating expenses: Research and development $ 7,607 $ 6,096 General and administrative 4,600 4,336 Total operating expenses 12,207 10,432 Loss from operations Total other expense Net loss Unrealized gain on short-term investments 91 — Comprehensive loss Net loss per share, basic and diluted $ $ Weighted-average common shares outstanding, basic and diluted 3..."
05/05/2023 8-K/A Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "8-K/A",
"CONSULTING AGREEMENT This consulting agreement is made by and between VIRACTA THERAPEUTICS, INC., having a place of business at 2533 South Coast Hwy 101, Suite 210, Cardiff, CA 92007 USA, together with its affiliates and Lisa Rojkjaer, M.D., an individual with a place of business at [***] , effective on the 5th day of May, 2023 at 4:59pm PDT for the purpose of setting forth the exclusive terms and conditions by which Company will acquire Consultant's services on a temporary basis. 1. WORK AND PAYMENT. Attached to this Agreement as is a project assignment describing the work Consultant will perform . This Project Assignment, and any future Project Assignment, will be subject to the terms and conditions of this Agreement and will set forth at a minimum the following terms: Consultant's rate ..."
05/02/2023 8-K Quarterly results
04/27/2023 ARS Form ARS - Annual Report to Security Holders:
04/27/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/31/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/14/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/14/2023 10-K Annual Report for the period ended December 31, 2022
03/13/2023 8-K Quarterly results
Docs: "Viracta Therapeutics, Inc. Selected Balance Sheet Highlights December 31, 2022 2021 Cash, cash equivalents and short-term investments $ 91,043 $ 103,554 Total assets $ 95,991 $ 108,552 Total liabilities $ 34,888 $ 14,181stockholders' equity $ 61,103 $ 94,371 Viracta Therapeutics, Inc. Condensed Consolidated Statement of Operations and Comprehensive Loss Three Months Ended December 31, Year Ended December 31, 2022 2021 2022 2021 Operating expenses: Research and development $ 6,703 $ 7,303 $ 26,262 $ 23,861 Purchased and acquired in-process research and development — — — 88,478 General and administrative 4,871 4,015 24,327 15,437 Total operating expenses 11,574 11,318 50,589 127,776 Gain on Royalty Purchase Agreement — — — 13,500 Loss from operations Total other income 1,248 1,392 Net loss..."
01/10/2023 SC 13D/A Schindel Yair Chaim reports a 19.4% stake in Viracta Therapeutics, Inc.
11/10/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/10/2022 8-K Quarterly results
09/19/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Executive Employment Agreement by and between the Company and Mark Rothera",
"Separation Agreement and Release by and between the Company and Ivor Royston",
"Viracta Therapeutics Announces Chief Executive Officer Leadership Succession to Drive the Next Phase of the Company's Strategic Development and Growth"
08/26/2022 8-K Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...
Docs: "FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT is entered into as of August 26, 2022, by and among SILICON VALLEY BANK, a California corporation with an office located at 3003 Tasman Drive, Santa Clara, CA 95054, as collateral agent , the Lenders listed on Schedule 1.1 thereof or otherwise a party thereto from time to time including SVB in its capacity as a Lender, and OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, VA 22314 , Viracta Therapeutics, Inc., a Delaware corporation, and Viracta Subsidiary, Inc., Delaware corporation, each with offices located at 2533 S Coast Hwy 101, Suite 210, Cardiff, CA 92007 . A. Collateral Agent, Borrower and Lenders have en..."
08/11/2022 8-K Quarterly results
08/09/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/09/2022 8-K Quarterly results
07/08/2022 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
06/27/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
06/08/2022 8-K Quarterly results
05/10/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/10/2022 8-K Quarterly results
04/27/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
04/27/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/27/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/15/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/18/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy